PFI ANDA
This article was originally published in The Tan Sheet
Executive Summary
Pharmaceutical Formulations, Inc.'s ibuprofen/pseudoephedrine hydrochloride tablets (Whitehall-Robins' Advil Cold & Sinus) approved by FDA April 8. ANDA 75-588 marks second private label approval referencing the analgesic. Ranbaxy Pharmaceuticals subsidiary Ohm Labs, which licensed its product to Perrigo, received 180-day, first-to-file exclusivity (1"The Tan Sheet" May 7, 2001, p. 8)...
You may also be interested in...
Perrigo New Product Launches, PPA Replacements Slated For August
Perrigo expects to offer famotidine Acid Reducer, a generic version of J&J/Merck's Pepcid AC, no later than June, the private labeler told analysts during a conference call May 1.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.